© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
September 13, 2021
The 12-month recurrence-free survival rate was 42.9% for those who received BCG alone compared with 44.4% for those who received the combination.
September 11, 2021
Long-term findings from 2 cohorts of a phase 3 study showed sustained efficacy with the novel intravesical gene therapy in patients with BCG-unresponsive non–muscle invasive bladder cancer.
Antibody titers and fold changes may prove to be a prognostic marker for the efficacy of nadofaragene firadenovec.
September 28, 2020
The addition of avelumab to standard first-line gemcitabine/carboplatin did not improve outcomes in patients with metastatic urothelial carcinoma.